(Reuters) – Japan’s Astellas Pharma Inc (T:) said on Monday it had agreed to buy Audentes Therapeutics Inc (O:) for $2.7 billion in cash as it looks to bolster its position in the gene therapy market.
Astellas offer of $60 per share represents a 110% premium to Audentes closing price on Monday.
The deal is expected to close in the first quarter of 2020, the companies said in a statement.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.